Ophthalmology · New York, NY
NPI
1609968833
Since 2006
Specialty
Ophthalmology
Code 207W00000X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
202 Canal St, Ste 401
New York, NY, 10013
Phone (212) 966-7583
Medicare paid, 2024
$62K
874 services
Medicare patients, 2024
137
Average age 76
Drug cost, 2024
$3.4M
10,509 prescriptions
Company payments, 2025
$695
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Andrew Naing was code 99213 (office e&m - established), 214 times for 96 patients. In total Andrew Naing billed 874 services in 28 codes, and Medicare paid $62K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-05-24.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 214 | 96 | $66.90 | $14K |
| 92202 Ophthalmological E&M | Office | 104 | 104 | $11.87 | $1,234 |
| 92083 Vision, Hearing, and Speech Services | Office | 93 | 76 | $49.35 | $4,589 |
| 99214 Office E&M - Established | Office | 92 | 91 | $98.54 | $9,066 |
| 92133 Computerized Ophthalmic Imaging | Office | 88 | 82 | $28.56 | $2,513 |
| 92286 Standard X-ray | Office | 82 | 82 | $32.44 | $2,660 |
| 92134 Computerized Ophthalmic Imaging | Office | 40 | 37 | $28.17 | $1,127 |
| 92250 Angiography | Office | 35 | 35 | $26.43 | $925 |
| 92020 Ophthalmological E&M | Office | 35 | 35 | $22.80 | $798 |
| 92136 Ultrasound - Nonspecific | Office | 18 | 12 | $31.28 | $563 |
By year: 2022 $119K for 1,769 services; 2023 $81K for 1,271 services; 2024 $62K for 874 services.
Medicare prescription drug claims, 2024
In 2024, the drug Andrew Naing prescribed most often to Medicare patients was Restasis (Cyclosporine), with 2,359 prescriptions and refills. In total Andrew Naing wrote 10,509 Medicare prescriptions that cost $3.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Restasis Cyclosporine | 2,359 | 2,575 | 443 | $1.6M |
| Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat | 812 | 1,343 | 174 | $9,250 |
| Latanoprost Generic | 773 | 1,210 | 161 | $7,004 |
| Brimonidine Tartrate Generic | 620 | 754 | 116 | $52K |
| Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha | 577 | 579 | 153 | $6,851 |
| Lumigan Bimatoprost | 553 | 852 | 109 | $240K |
| Rhopressa Netarsudil Mesylate | 459 | 663 | 89 | $238K |
| Prednisolone Acetate Generic | 441 | 524 | 217 | $22K |
| Rocklatan Netarsudil Mesylat/Latanoprost | 404 | 576 | 76 | $218K |
| Xiidra Lifitegrast | 384 | 403 | 62 | $271K |
| Erythromycin Erythromycin Base | 327 | 329 | 102 | $3,709 |
| Timolol Maleate Generic | 297 | 481 | 93 | $4,012 |
| Tyrvaya Varenicline Tartrate | 278 | 284 | 74 | $185K |
| Cyclosporine Generic | 246 | 293 | 74 | $68K |
| Alphagan P Brimonidine Tartrate | 196 | 226 | 41 | $76K |
Brand drugs: 6,522 claims; generic drugs: 3,987 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Andrew Naing $695 ($695 in general payments such as food, travel and fees) from 5 companies. The largest payer was Glaukos Corporation with $582.
| Company | Payments | Amount |
|---|---|---|
| Glaukos Corporation GKOS | 4 | $582 |
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 1 | $60.7 |
| Abbvie Inc. ABBV | 1 | $21.51 |
| Bausch & Lomb Americas Inc. BLCO | 1 | $15.77 |
| Sight Sciences, Inc. SGHT | 1 | $14.67 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.